CN104622927A - External sulfanilamide powder - Google Patents
External sulfanilamide powder Download PDFInfo
- Publication number
- CN104622927A CN104622927A CN201410857783.5A CN201410857783A CN104622927A CN 104622927 A CN104622927 A CN 104622927A CN 201410857783 A CN201410857783 A CN 201410857783A CN 104622927 A CN104622927 A CN 104622927A
- Authority
- CN
- China
- Prior art keywords
- external
- sulfamethoxazole
- percentage composition
- kinds
- sulfanilamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses external sulfanilamide powder, and belongs to the technical field of anti-inflammatory drugs. The external sulfanilamide powder disclosed by the invention is prepared from the following components by percent: 70%-80% of sulfamethoxazole, 10%-15% of trimethoprim, 5%-10% of dexamethasone, 1%-2% of rifamycin, 1%-2% of volatile crystal and 2%-2.7% of panax notoginseng, wherein the volatile crystal is a plum film or borneol. According to the external sulfanilamide powder, through interaction and mutual restrictioneffects of kinds of components, skin itching of allergic persons caused by the defect that single-dosage sulfamethoxazole in the prior art easily generates drug resistance on kinds of bacteria when being used in the prior art is overcome; the treatment effect can be relatively well reached; and the external sulfanilamide powder can be widely applied to treatment of klebsiella, enterobacter, proteus mirabilis, shigella infection, nontuberculosis mycobacteriainfection, legionella pneumophilainfection, kinds of traumaticskin infections and abscessinflammation, and is free of anaphylactic reaction.
Description
Technical field
The invention belongs to antibiotic medicine technical field, particularly a kind of SN.
Background technology
Circulate on the market at present and commonly in the class medicine such as compound sulfamethoxazole and trimethoprim tablets agent, Dexaport, rifampicin capsules, the Borneolum Syntheticum crystalline solid of Chinese medicinal ingredients, Radix Notoginseng (the having another name called Radix Notoginseng) dry product of Chinese medicinal ingredients that uses be widely used in pain relieving, hemostasis, people and animals that are antibacterial and antiinflammatory share medicine, but sulfonamides intermediate is for oral administration can be caused minority crowd and occur skin allergy once in a while, occur that skin Pruritus, redness are as untoward reaction such as urticaria shapes, and single Use Limitation fruit is not good.Therefore seek a kind of medicament for pain relieving, hemostasis, antibacterial and antiinflammatory, after avoiding the user suffering from wound to take, occur that allergic symptom seems particularly important and has practical significance.
Summary of the invention
For overcoming the shortcoming and deficiency that exist in prior art, primary and foremost purpose of the present invention is to provide a kind of SN.The SN that the present invention obtains by between each component with the use of, outward for patient injury outward, the anaphylaxis caused when single oral formulations can be avoided to take.
Another object of the present invention is the preparation method providing above-mentioned SN.
Object of the present invention is achieved through the following technical solutions: a kind of SN, is made up of the component of following percentage composition:
Described volatile crystals are borneol or Borneolum Syntheticum.
Described Radix Notoginseng is Notoginseng Root.
Described SN, is preferably made up of the component of following percentage composition:
Described SN, is preferably made up of the component of following percentage composition:
Described SN, is preferably made up of the component of following percentage composition:
The preparation method of described SN, specifically comprise the following steps: by above-mentioned percentage composition Sulfamethoxazole, trimethoprim, dexamethasone, rifamycin, volatile crystals and panax mixed after, cross 500 ~ 600 mesh sieves, prepare SN.
The SN that the present invention prepares is more suitable for Klebsiella, Enterobacter, proteus mirabilis, Shigella infection, non-tuberculous mycobacteria infects, Legionnella infects and various traumatic skin infects, the treatment of abscess type inflammation.The SN safe and applicable that the present invention obtains is in various traumatic, multifarious various wound, extreme misery scalds burn, erosive vaginitis, the moon assist the patient that inflammation, eczema, bleb are examined, virus infected herpes, vesicle skin ulcer, pellagra, oral ulcer etc. are sick to treat, also be specially adapted to the treatment of carrying, provide for oneself, saving oneself of equipping soldier and disaster area trauma type patient, and long-term observation is paid a return visit all evident in efficacy, does not find untoward reaction.
The outward appearance that the present invention obtains SN is pink powder shape, only the outer hemostasis for patient wound, pain relieving, detumescence, antiinflammatory six doses of formula SNs.
The present invention has following advantage and effect relative to prior art:
The interaction of various composition and the effect of mutually restriction in SN in the present invention, to overcome in prior art single dose formula Sulfamethoxazole and in use easy allergy sufferers skin Pruritus is caused for all kinds bacterium shortcoming that easily develops immunity to drugs, therefore above six doses of formulas mixing dosage form can reach therapeutic effect better.The SN that the present invention obtains can be widely used in Klebsiella, Enterobacter, proteus mirabilis, Shigella infection, non-tuberculous mycobacteria infects, Legionnella infects and various traumatic skin infects, the treatment of abscess type inflammation; Occur without anaphylaxis.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is described in further detail, but embodiments of the present invention are not limited thereto.
Embodiment 1
A kind of SN, is made up of the component of following percentage composition:
The preparation method of described SN, specifically comprise the following steps: by above-mentioned percentage composition Sulfamethoxazole, trimethoprim, dexamethasone, rifamycin, borneol and Notoginseng Root mixing after, cross 500 ~ 600 mesh sieves, prepare SN.
Embodiment 2
A kind of SN, is made up of the component of following percentage composition:
The preparation method of described SN, specifically comprise the following steps: by above-mentioned percentage composition Sulfamethoxazole, trimethoprim, dexamethasone, rifamycin, borneol and Notoginseng Root mixing after, cross 500 ~ 600 mesh sieves, prepare SN.
Embodiment 3
The preparation method of described SN, specifically comprise the following steps: by above-mentioned percentage composition Sulfamethoxazole, trimethoprim, dexamethasone, rifamycin, borneol and Notoginseng Root mixing after, cross 500 ~ 600 mesh sieves, prepare SN.
Embodiment 4
A kind of SN, is made up of the component of following percentage composition:
The preparation method of described SN, specifically comprise the following steps: by above-mentioned percentage composition Sulfamethoxazole, trimethoprim, dexamethasone, rifamycin, Borneolum Syntheticum and Notoginseng Root mixing after, cross 500 ~ 600 mesh sieves, prepare SN.
Embodiment 5
A kind of SN, is made up of the component of following percentage composition:
The preparation method of described SN, specifically comprise the following steps: by above-mentioned percentage composition Sulfamethoxazole, trimethoprim, dexamethasone, rifamycin, Borneolum Syntheticum and Notoginseng Root mixing after, cross 500 ~ 600 mesh sieves, prepare SN.
Embodiment 3
The preparation method of described SN, specifically comprise the following steps: by above-mentioned percentage composition Sulfamethoxazole, trimethoprim, dexamethasone, rifamycin, Borneolum Syntheticum and Notoginseng Root mixing after, cross 500 ~ 600 mesh sieves, prepare SN.
The SN that embodiment 1 ~ 6 prepares is more suitable for Klebsiella, Enterobacter, proteus mirabilis, Shigella infection, non-tuberculous mycobacteria infects, Legionnella infects and various traumatic skin infects, the treatment of abscess type inflammation.The SN safe and applicable obtained is in various traumatic, multifarious various wound, extreme misery scalds burn, erosive vaginitis, the moon assist the patient that inflammation, eczema, bleb are examined, virus infected herpes, vesicle skin ulcer, pellagra, oral ulcer etc. are sick to treat, also be specially adapted to the treatment of carrying, provide for oneself, saving oneself of equipping soldier and disaster area trauma type patient, and long-term observation is paid a return visit all evident in efficacy, does not find untoward reaction.
The outward appearance that the present invention obtains SN is the pink powder shape only outer hemostasis for patient wound, pain relieving, detumescence, antiinflammatory six doses of formula SNs.
The SN that embodiment 1 ~ 6 obtains is applied to various wound or extreme misery scalds burn, erosive vaginitis, the moon assist the diseases such as inflammation, eczema, bleb are examined, virus infected herpes, vesicle skin ulcer, pellagra, oral ulcer, compared to oral administered compound Sulfamethoxazole, allergy sufferers skin pruritus can not be caused, there is good therapeutic effect.
Above-described embodiment is the present invention's preferably embodiment; but embodiments of the present invention are not restricted to the described embodiments; change, the modification done under other any does not deviate from spirit of the present invention and principle, substitute, combine, simplify; all should be the substitute mode of equivalence, be included within protection scope of the present invention.
Claims (7)
1. a SN, is characterized in that: be made up of the component of following percentage composition:
2. SN according to claim 1, is characterized in that: described volatile crystals are borneol or Borneolum Syntheticum.
3. SN according to claim 1, is characterized in that: described Radix Notoginseng is Notoginseng Root.
4. SN according to claim 1, is characterized in that: be made up of the component of following percentage composition:
5. SN according to claim 1, is characterized in that: be made up of the component of following percentage composition:
6. SN according to claim 1, is characterized in that: be made up of the component of following percentage composition:
7. the preparation method of the SN described in any one of claim 1 ~ 6, it is characterized in that: specifically comprise the following steps: by the percentage composition described in any one of claim 1 ~ 6 Sulfamethoxazole, trimethoprim, dexamethasone, rifamycin, volatile crystals and panax mixed after, cross 500 ~ 600 mesh sieves, prepare SN.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410857783.5A CN104622927A (en) | 2014-12-27 | 2014-12-27 | External sulfanilamide powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410857783.5A CN104622927A (en) | 2014-12-27 | 2014-12-27 | External sulfanilamide powder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104622927A true CN104622927A (en) | 2015-05-20 |
Family
ID=53202489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410857783.5A Pending CN104622927A (en) | 2014-12-27 | 2014-12-27 | External sulfanilamide powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104622927A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105147706A (en) * | 2015-09-22 | 2015-12-16 | 古东晖 | Skin disinfection and itching-relieving composite and preparation method and application thereof |
| CN105748490A (en) * | 2016-02-26 | 2016-07-13 | 陈鲜 | Quick scald-healing powder and using method thereof |
| CN108379491A (en) * | 2018-05-16 | 2018-08-10 | 邱皓升 | A kind of antiphlogistic powder and preparation method thereof |
| CN111437392A (en) * | 2020-04-22 | 2020-07-24 | 卢丽菊 | Biological medicine wound surface anti-inflammatory lotion |
| WO2021189444A1 (en) * | 2020-03-24 | 2021-09-30 | 中国人民解放军海军军医大学 | Use of rifamycin antibiotics in preparation of drugs against yellow fever virus infections |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101129522A (en) * | 2007-08-27 | 2008-02-27 | 滕大浪 | Exterior-applied medicine for treating dermatopathy |
| CN102205023A (en) * | 2011-05-20 | 2011-10-05 | 胡三明 | Powder for diminishing inflammation and healing trauma |
| CN104069326A (en) * | 2014-07-11 | 2014-10-01 | 杨华 | Medicine combination preparation as well as preparation method and application thereof |
-
2014
- 2014-12-27 CN CN201410857783.5A patent/CN104622927A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101129522A (en) * | 2007-08-27 | 2008-02-27 | 滕大浪 | Exterior-applied medicine for treating dermatopathy |
| CN102205023A (en) * | 2011-05-20 | 2011-10-05 | 胡三明 | Powder for diminishing inflammation and healing trauma |
| CN104069326A (en) * | 2014-07-11 | 2014-10-01 | 杨华 | Medicine combination preparation as well as preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 陈瑞玲: "磺胺类药与甲氧苄啶的合理应用", 《中国临床医生》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105147706A (en) * | 2015-09-22 | 2015-12-16 | 古东晖 | Skin disinfection and itching-relieving composite and preparation method and application thereof |
| CN105748490A (en) * | 2016-02-26 | 2016-07-13 | 陈鲜 | Quick scald-healing powder and using method thereof |
| CN108379491A (en) * | 2018-05-16 | 2018-08-10 | 邱皓升 | A kind of antiphlogistic powder and preparation method thereof |
| WO2021189444A1 (en) * | 2020-03-24 | 2021-09-30 | 中国人民解放军海军军医大学 | Use of rifamycin antibiotics in preparation of drugs against yellow fever virus infections |
| CN111437392A (en) * | 2020-04-22 | 2020-07-24 | 卢丽菊 | Biological medicine wound surface anti-inflammatory lotion |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104622927A (en) | External sulfanilamide powder | |
| US9662360B2 (en) | Treatment of herpes, pseudomonas, staph, and hepatitis | |
| JP2018513188A5 (en) | ||
| RU2012148710A (en) | ORGANIC COMPOUND FOR USE IN TREATMENT OF LIVER CANCER | |
| RU2010105122A (en) | COMPOSITIONS FOR CARE OF THE ORAL CAVITY, PRODUCTS AND METHODS OF APPLICATION | |
| ES2834985T3 (en) | Composition containing cineole for nasal administration | |
| RU2010104848A (en) | CRYSTAL FORM 4 - [[4 - [[4- (2-CYANETHENYL) -2,6-DIMETHYLPHENYL] AMINO] -2-PYRIMIDINYL] AMINO] BENZONITRIL | |
| JP2009530350A (en) | Spray composition for topical use for the treatment and / or prevention of cold sore infection | |
| BR112017026417B1 (en) | FORMULATION FOR THE TREATMENT OF MOUTH, THROAT AND RESPIRATORY TRACT DISORDERS | |
| Yarom et al. | The efficacy of minocycline mouth rinses on the symptoms associated with recurrent aphthous stomatitis: a randomized, double-blind, crossover study assessing different doses of oral rinse | |
| US20130123319A1 (en) | Medthod of Treating a systemic inflammatory disorder and damaged internal tissues | |
| JP2016505050A5 (en) | ||
| US10888541B2 (en) | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker | |
| US20120225143A1 (en) | Cold sore formulation and related method of manufacture | |
| Agnihotri et al. | Oral Ulceration and Indian Herbs: A Scoping Review | |
| RU2013105513A (en) | Derivatives of 1-aminoalkylcyclohexane for the treatment of inflammatory skin diseases | |
| JP2019535830A5 (en) | ||
| JP2002308764A (en) | Pharmaceutical composition for ophthalmic use | |
| JP2011246451A (en) | Anti-inflammatory agent composition | |
| CN102631406A (en) | Mouthwash for oral ulcer | |
| ES2538335T3 (en) | Combination of polyacrylic acid and 2-amino-2-methylpropanol for use in the treatment of herpes infections | |
| CN103585330B (en) | A kind of Chinese medicine composition for cutaneous fungal infection and preparation method thereof | |
| US20130316017A1 (en) | Oral Composition for the Treatment of Acne | |
| JP2006008540A (en) | Cold remedy | |
| ES2926475T3 (en) | Neem for the treatment of RLS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150520 |